NCT03537950View on ClinicalTrials.gov

Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder

NACompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 22, 2016

Primary Completion Date

February 16, 2017

Study Completion Date

March 1, 2017

Conditions
Autism Spectrum Disorder
Interventions
DRUG

PLC

Single oral dose of PLC.

DRUG

CBD

Single oral dose of cannabidiol (CBD) - 600mg.

DRUG

CBDV

Single oral dose of cannabidivarin (CBDV) - 600mg.

Trial Locations (1)

SE5 8AF

King's College London, London

All Listed Sponsors
lead

King's College London

OTHER

NCT03537950 - Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter